A5001082208- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- Monoclonal and Polyclonal Antibodies Research
- Cancer, Hypoxia, and Metabolism
- Medical Imaging and Pathology Studies
- DNA Repair Mechanisms
- Quinazolinone synthesis and applications
- Bioinformatics and Genomic Networks
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Telomeres, Telomerase, and Senescence
- Lung Cancer Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- HER2/EGFR in Cancer Research
- MicroRNA in disease regulation
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Histone Deacetylase Inhibitors Research
- Ocular Oncology and Treatments
Ospedale Santa Maria
2017-2021
Azienda Ospedaliera di Perugia
2011-2020
Misericordia University
2013-2019
University of Perugia
2015-2018
Besides platinum-based chemotherapy, no established treatment option exists for advanced non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 (Ex20ins) insertion mutations. We sought to determine the clinical outcome of this mutation subtype in immunotherapy era. Thirty NSCLCs Ex20ins mutations were identified, whom 15 had received immune checkpoint blockade (ICB) as monotherapy (N = 12), combination chemotherapy 2) or another immunotherapeutic agent 1). The response rate was...
Risk assessment and treatment choice remains a challenge in early non-small-cell lung cancer (NSCLC). The aim of this study was to identify novel genes involved the risk relapse (ER) compared no (NR) resected adenocarcinoma (AD) patients using combination high throughput technology computational analysis. We identified 18 (n.13 NR n.5 ER) with stage I AD. Frozen samples ER, corresponding normal (NL) were subjected Microarray quantitative-PCR (Q-PCR). A gene network analysis performed select...
// Marianna Penzo 1 , Vienna Ludovini 2 Davide Treré Annamaria Siggillino Jacopo Vannucci 3 Guido Bellezza 4 Lucio Crinò Lorenzo Montanaro Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University Bologna, I-40138, Italy Medical Oncology, S. Maria della Misericordia Hospital, Perugia, I-06156, Thoracic Surgery, Institute Pathological Anatomy Histology, Correspondence to: Montanaro, e-mail: lorenzo.montanaro@unibo.it Keywords: lung cancer,...
// Elisa Baldelli 1,2 , Guido Bellezza 3 Eric B. Haura 4 Lucio Crinó 2 W. Douglas Cress Jianghong Deng 1 Vienna Ludovini Angelo Sidoni Matthew Schabath Francesco Puma 5 Jacopo Vannucci Annamaria Siggillino Lance A. Liotta Emanuel F. Petricoin III and Mariaelena Pierobon Center for Applied Proteomics Molecular Medicine, George Mason University, Manassas, VA, USA Medical Oncology Division, S. Maria della Misericordia Hospital, Perugia, Italy Department of Experimental Section Anatomic...
Programmed death ligand 1 (PD-L1) expression is a predictive biomarker of the success PD-1/PD-L1 inhibitor therapy for patients with advanced non-small cell lung cancer (NSCLC) but its role as prognostic marker early-stage resectable NSCLC remains unclear. We studied gene levels immune-related genes PD-1, PD-L1, PD-L2, IDO-1, IDO-2 and INFγ in tumor tissue surgically resected correlated finding clinicopathological features patient outcomes. A total 191 consecutive who underwent curative...
We investigated the frequency of MYC and TERC increased gene copy number (GCN) in early-stage non-small cell lung cancer (NSCLC) evaluated correlation these genomic imbalances with clinicopathologic parameters outcome.Tumor tissues were obtained from 113 resected NSCLCs. GCNs tested by fluorescence situ hybridization (FISH) according to University Colorado Cancer Center (UCCC) criteria based on receiver operating characteristic (ROC) classification.When UCCC applied, 41 (36%) cases for...
This case describes a novel KRAS Q22K mutation with simultaneous polysomy in patient advanced, enteric-type, adenocarcinoma of the lung.Despite administration systemic chemotherapy, disease underwent rapid progression and led to patient's death short period time.Such an aggressive clinical course suggests that, this specific case, dependency was major genetic driver poor prognosis.Direct deoxy ribonucleic acid (DNA) sequencing gene allows for detection mutations, it might be advocated...
Analysis of circulating cell-free tumor DNA (cftDNA) has emerged as a specific and sensitive blood-based approach to detect epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients. Still, there is some debate on what should be the preferential clinical method for plasma-derived cftDNA analysis. We tested 31 NSCLC patients treated with anti-EGFR tyrosine kinase inhibitors (TKIs), at baseline serially during therapy, by comparing three methodologies...
The aim of the present study was to assess expression select DNA repair and synthesis genes in non-small-cell lung cancer (NSCLC) according KRAS mutation status. ERCC1, TS, RRM1, BRCA1 mRNA levels were assessed from either primary or metastatic tumor specimens patients diagnosed with epidermal growth factor receptor (EGFR) wild‑type (WT) advanced NSCLC. Total RNA isolated paraffin‑embedded using RNeasy FFPE kit automatically purified a QiaCube instrument. Quantification analyzed by real‑time...
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of lung cancer. However, their clinical benefit is limited to a minority patients. To unravel immune-related factors that are predictive sensitivity or resistance immunotherapy, we performed gene expression analysis by RNA-Seq using Oncomine Immuno Response Assay (OIRRA) on total 33 advanced NSCLC patients treated with ICI evaluating levels 365 genes. We found four genes (CD1C, HLA-DPA1, MMP2, and TLR7) downregulated (p...
Preoperative chemotherapy may play a role in postoperative respiratory complications due to subclinical parenchymal damage. We investigated the gene expression of lung tissue components after neoadjuvant alveolar-capillary membrane, extracellular matrix and membrane proteins.The study group included 14 patients submitted pulmonary resection for cancer 3 cycles gemcitabine-cisplatin, while control naive-treatment patients. RNA was extracted from frozen obtained by healthy specimens using EZ1...
In this work high throughput technology and computational analysis were used to study two stage IV lung adenocarcinoma patients treated with standard chemotherapy markedly different survival (128 months vs 6 months, respectively) whose tumor samples exhibit a dissimilar protein activation pattern of the signal transduction. Tumor subjected Reverse Phase Protein Microarray (RPPA) explore expression/activation levels 51 signaling proteins. We selected most divergent proteins based on ratio...
7562 Background: Specific EGFR tyrosine Kinase inhibitors (TKIs) have been developed and used for the treatment of advanced NSCLC. Somatic activating mutations gene some clinical pathological features associated with tumor response favourable outcome these agents. However, that initially respond to EGFR-TKIs almost inevitably become resistant later. We present a comprehensive analysis MET, EGFR, KRAS PIK3CA in NSCLC patients treated TKIs, aim clarifying relative contribution molecular...
11099 Background: Surgically resected early-stage non-small lung cancer (NSCLC) display a highly variable outcome in terms of PFS and OS. Currently used clinico-pathological parameters may not precisely predict individual risk relapse. Here, we correlated the levels circulating miRNAs with OS early stage fully NSCLCs. Methods: We analyzed 84 most abundant (Qiagen PCR array) sera from patients IàIIIA NSCLC. All were collected at time diagnosis. Total serum RNA was purified miRNA measured by...
e18023 Background: Treatment with a reversible EGFR-TKI may benefit pts EGFR WT advanced NSCLC, though to much lesser extent than carrying an activating mutation in the gene. We assessed whether KRAS mutational status would help predict sensitivity gefitinib or erlotinib NSCLC pts. Methods: Sixty-seven WT, treated any line setting were included. Pts from May 2005 March 2011 at Medical Oncology of Perugia Hospital. (exons 18 21) and (codons 12, 13 61) genes amplified by nested PCR sequenced...